
Fujie Xu, PhD
Co-Director of Global Health Program and Professor, Duke Kunshan University
Dr. Fujie Xu is an infectious disease physician and an epidemiologist with nearly 30 years of experience in public health research and project management in the United States, China and around the world. She joined DKU as the Co-Director of the Global Health Program in January 2025. In this role, Dr. Xu is dedicated to minimize all existing or emerging infectious disease threats and promote the vision of “health for all” by cultivating a new generation of global health talents.
Dr. Xu will focus on health innovations and their implementation. Her research and project interests will cover:
- Develop health innovations to address infectious diseases and possible pandemics, including applying genomic sequencing technology to understand the transmission dynamics and to detect emerging infections or variants and guide the development of countermeasures of vaccines and diagnostics; collaborating with Duke-NUS to introduce the technology into Asian countries (check the initiative); and accelerating the innovation and adoption of NGS for global health.
- Promote evidence generation, guideline development, and partnership to create real-world impact, including enhancing the partnership with public and private sectors that may involve government agencies, pharmaceutical or biotechnology companies, academia, and philanthropic funders in China and beyond for advocacy and global health practices.
Dr. Xu graduated from Peking Medical University (currently the Peking University Health Science Center) and received her PhD in Epidemiology from the Rollins School of Public Health, Emory University. Her past career experiences include the United States Centers for Disease Control and Prevention, Gilead Sciences, and Zhejiang University. In May 2020, she joined the Bill & Melinda Gates Foundation China Country Office as Deputy Director for Health Innovation and Partnerships to accelerate the development of vaccines, diagnostics and antimicrobials against pandemic and endemic infectious diseases.